Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

• Published in: JAMA oncology Vol. 2; no. 11; p. 1441
• Main Authors: Scher, Howard I, Lu, David, Schreiber, Nicole A, Louw, Jessica, Graf, Ryon P, Vargas, Hebert A, Johnson, Ann, Jendrisak, Adam, Bambury, Richard, Danila, Daniel, McLaughlin, Brigit, Wahl, Justin, Greene, Stephanie B, Heller, Glenn, Marrinucci, Dena, Fleisher, Martin, Dittamore, Ryan
• Format: Journal Article
• Language: English
• Published: United States 01-11-2016
• Subjects: Aged; Aged, 80 and over; Androgen Receptor Antagonists - pharmacology; Androgen Receptor Antagonists - therapeutic use; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor; Cross-Sectional Studies; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins - blood; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating - metabolism; Proportional Hazards Models; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - diagnosis; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - therapy; Protein Isoforms - genetics; Protein Isoforms - metabolism; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; Sensitivity and Specificity; Taxoids - pharmacology; Taxoids - therapeutic use; Treatment Outcome
• ISSN: 2374-2445
• DOI: 10.1001/jamaoncol.2016.1828

A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane.
To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes.
For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with progressive mCRPC undergoing a change in treatment were considered; 86 were excluded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time constraints, leaving 161 patients for analysis. Between December 2012 and March 2015, blood was collected and processed from patients with progressive mCRPC immediately prior to new line of systemic therapy. Patients were followed up to 3 years.
Prostate-specific antigen (PSA) response, time receiving therapy, radiographic progression-free survival (rPFS), and overall survival (OS).
Overall, of 193 prospectively collected blood samples from 161 men with mCRPC, 191 were evaluable (128 pre-ARS inhibitor and 63 pretaxane). AR-V7-positive CTCs were found in 34 samples (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples. Patients whose samples had AR-V7-positive CTCs before ARS inhibition had resistant posttherapy PSA changes (PTPC), shorter rPFS, shorter time on therapy, and shorter OS than those without AR-V7-positive CTCs. Overall, resistant PTPC were seen in 65 of 112 samples (58%) without detectable AR-V7-positive CTCs prior to ARS inhibition. There were statistically significant differences in OS but not in PTPC, time on therapy, or rPFS for patients with or without pretherapy AR-V7-positive CTCs treated with a taxane. A multivariable model adjusting for baseline factors associated with survival showed superior OS with taxanes relative to ARS inhibitors when AR-V7-positive CTCs were detected pretherapy (hazard ratio, 0.24; 95% CI, 0.10-0.57; P = .035).
The results validate CTC nuclear expression of AR-V7 protein in men with mCRPC as a treatment-specific biomarker that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical practice setting. Continued examination of this biomarker in prospective studies will further aid clinical utility.